Structure Therapeutics faces revised price target amid competitive pressure in the oral weight-loss drug market.
H.C. Wainwright lowered its price target for Structure Therapeutics (NASDAQ:GPCR) to $70 from $100, citing rising competition in the mid-body mass index market. The new target still implies over 61% upside potential, and the firm retained its Buy rating on the stock.
The reduction follows the emergence of Pfizer’s once-monthly injectable and Retatrutide’s strong low-dose profile, which set new benchmarks. Structure Therapeutics recently reported Phase 2b trial results for aleniglipron, showing sustained weight loss beyond 36 weeks with improved tolerability at a lower 2.5 mg dose.
Phase 3 trials for aleniglipron are scheduled to begin in the third quarter of 2026. The company focuses on oral small molecule therapies for chronic diseases with unmet medical needs.